- Home
- NUVL vs SNEX Comparison
NUVL vs SNEX Comparison
Compare NUVL & SNEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- SNEX
- Stock Information
- Founded
- NUVL 2017
- SNEX 1924
- Country
- NUVL United States
- SNEX United States
- Employees
- NUVL 200
- SNEX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- SNEX Investment Bankers/Brokers/Service
- Sector
- NUVL Health Care
- SNEX Finance
- Exchange
- NUVL Nasdaq
- SNEX Nasdaq
- Market Cap
- NUVL 6.0B
- SNEX 5.3B
- IPO Year
- NUVL 2021
- SNEX 1994
- Fundamental
- Price
- NUVL $83.09
- SNEX $98.15
- Analyst Decision
- NUVL Strong Buy
- SNEX Buy
- Analyst Count
- NUVL 9
- SNEX 1
- Target Price
- NUVL $118.89
- SNEX N/A
- AVG Volume (30 Days)
- NUVL 396.7K
- SNEX 517.9K
- Earning Date
- NUVL 11-11-2025
- SNEX 11-18-2025
- Dividend Yield
- NUVL N/A
- SNEX N/A
- EPS Growth
- NUVL N/A
- SNEX 21.85
- EPS
- NUVL N/A
- SNEX 5.86
- Revenue
- NUVL N/A
- SNEX $129,411,800,000.00
- Revenue This Year
- NUVL N/A
- SNEX N/A
- Revenue Next Year
- NUVL N/A
- SNEX $22.66
- P/E Ratio
- NUVL N/A
- SNEX $16.75
- Revenue Growth
- NUVL N/A
- SNEX 53.56
- 52 Week Low
- NUVL $55.54
- SNEX $54.60
- 52 Week High
- NUVL $106.32
- SNEX $106.98
- Technical
- Relative Strength Index (RSI)
- NUVL 56.32
- SNEX 50.52
- Support Level
- NUVL $81.02
- SNEX $97.40
- Resistance Level
- NUVL $86.34
- SNEX $105.33
- Average True Range (ATR)
- NUVL 3.63
- SNEX 3.16
- MACD
- NUVL 0.28
- SNEX 0.09
- Stochastic Oscillator
- NUVL 66.33
- SNEX 54.68
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.